| [1] |
Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014 [J]. JAMA, 2016, 316(6): 602-610.
|
| [2] |
Wang F, Yang C, Long J, et al. Executive summary for the 2015 annual data report of the China Kidney Disease Network (CK-NET) [J]. Kidney Int, 2019, 95(3): 501-505.
|
| [3] |
Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States [J]. Am J Kidney Dis, 2017, 69(3 Suppl 1): A7-A8.
|
| [4] |
Wen CP, Chang CH, Tsai MK, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years [J]. Kidney Int, 2017, 92(2): 388-396.
|
| [5] |
Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in US diabetes care, 1999-2010 [J]. N Engl J Med, 2013, 368(17): 1613-1624.
|
| [6] |
American Diabetes Association. Standards of medical care in diabetes-2019 [J]. Diabetes Care, 2019, 42 (Suppl 1): S1-S193.
|
| [7] |
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [J]. N Engl J Med, 1993, 329(14): 977-986.
|
| [8] |
Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC [J]. Diabetes, 2015, 64(2): 631-642.
|
| [9] |
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study [J]. Diabetes Res Clin Pract, 1995, 28(2): 103-117.
|
| [10] |
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes [J]. N Engl J Med, 2008, 359(15): 1577-1589.
|
| [11] |
Papademetriou V, Lovato L, Doumas M, et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes [J]. Kidney Int, 2015, 87(3): 649-659.
|
| [12] |
Wong MG, Perkovic V, Chalmers J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON [J]. Diabetes Care, 2016, 39(5): 694-700.
|
| [13] |
Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality [J]. JAMA, 2014, 311(24): 2518-2531.
|
| [14] |
Yun JS, Ko SH, Ko SH, et al. Presence of macroalbuminuria predicts severe hypoglycemia in patients with type 2 diabetes: a 10-year follow-up study [J]. Diabetes Care, 2013, 36(5): 1283-1289.
|
| [15] |
Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes [J]. Diabetes Care, 2017, 40(4): 538-545.
|
| [16] |
Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials [J]. Diabetes Care, 2019, 42(3): 400-405.
|
| [17] |
Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the lines-application to the individual patient [J]. Kidney Int, 2012, 82(8): 840-856.
|
| [18] |
Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis [J]. Lancet, 2012, 380(9854): 1662-1673.
|
| [19] |
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J]. N Engl J Med, 2001, 345(12): 851-860.
|
| [20] |
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J]. N Engl J Med, 2001, 345(12): 861-869.
|
| [21] |
Garofalo C, Borrelli S, Liberti ME, et al. SGLT2 inhibitors: nephroprotective efficacy and side effects [J]. Medicina (Kaunas), 2019, 55(6): 268.
|
| [22] |
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy [J]. N Engl J Med, 2019, 380(24): 2295-2306.
|
| [23] |
Satman I, R Rea R, Eriksson MJ, et al. LEADER-6: baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population [J]. Diabetes Complications, 2016, 30(8): 1631-1639.
|
| [24] |
Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial [J]. Lancet Diabetes Endocrinol, 2018, 6(8): 605-617.
|